Laryngeal Transplantation: Research, Clinical Experience, and Future Goals

ABSTRACT

The loss of a functional voice because of trauma or laryngectomy can have a devastating impact on a patient's self-esteem and overall quality of life. Unfortunately, even with advances in organ preservation therapy, total laryngectomy is frequently necessary in the treatment of laryngeal carcinoma. Over the past several years, the senior author initiated research into laryngeal transplantation with the goal of restoring lung-powered speech for these patients. The research led to the development of an animal model and several groundbreaking studies in this area. Investigations into the use of irradiation, single-drug and multidrug immunosuppression, and the effects of mammalian target of rapamycin (mTOR) inhibitors have produced significant insight into laryngeal allograft preservation. The laboratory research culminated in the first successful total laryngeal transplant in 1998. The patient had suffered significant laryngeal trauma and strongly desired return of laryngeal phonation. The patient has been maintained on multidrug immunosuppression with minimal difficulties. Now more than 8 years after the procedure, the patient continues to have an excellent voice and dramatically improved quality of life. Recent data suggest that altered immunosuppression schedules and the use of mTOR inhibitors may allow patients to minimize immunosuppression-related adverse effects and ameliorate the risk of developing recurrent or de novo carcinoma. These data, when considered in combination with the progress made over the past 14 years, lead us to believe that the future of laryngeal transplantation is bright.

KEYWORDS

Laryngeal allograft - immunosuppression

REFERENCES

• 1 Boles R. Surgical reimplantation of the larynx in dogs: a progress report.  Laryngoscope. 1966;  76 1057-1067
• 2 Ogura J H, Kawasaki M, Takenouchi S et al.. Replantation and Transplantation of the Canine Larynx.  Ann Otol Rhinol Laryngol. 1966;  75 295-312
• 3 Silver C E, Liebert P S, Som M L. Autologous transplantation of the canine larynx.  Arch Otolaryngol. 1967;  86 95-102
• 4 Takenouchi S, Ogura J H, Kawasaki M et al.. Autogenous transplantation of the canine larynx.  Laryngoscope. 1967;  7 1644
• 5 Kluyskens P, Ringoir S. Follow up of a human larynx transplantation.  Laryngoscope. 1970;  80 1244-1250
• 6 McNeil B J, Weichselbaum R, Pauker S. Speech and survival.  N Engl J Med. 1981;  305 982-987
• 7 Strome S, Sloman-Moll E, Samonte B, Wu J, Strome M. A rat model for a vascularized laryngeal allograft.  Ann Otol Rhinol Laryngol. 1992;  101 950-953
• 8 Potter C P, Birchall M A. Laryngectomee's views on laryngeal transplantation.  Transpl Int. 1998;  11 433-438
• 9 Lorenz R R, Dan O, Fritz M A et al.. Immunosuppressive effect of irradiation in the murine laryngeal transplantation model: a controlled trial.  Ann Otol Rhinol Laryngol. 2003;  112 712-715
• 10 Lewis R M, Janney R P, Golden D L et al.. Stability of renal allograft function associated with long-term cyclosporine immunosuppressive therapy-five year follow-up.  Transplantation. 1989;  47 266-272
• 11 Ferguson R M, Rynasiewicz J J, Sutherland D E et al.. Cyclosporin A in renal transplantation: a prospective randomized trial.  Surgery. 1982;  92 175-182
• 12 Starzl T E, Weil III R, Iwatsuki S et al.. The use of cyclosporin A and prednisone in cadaver kidney transplantation.  Surg Gynecol Obstet. 1980;  151 17-26
• 13 Starzl T E, Klintmalm G BG, Weil III R et al.. Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients.  Surg Gynecol Obstet. 1981;  153 486-494
• 14 Lorenz R, Dan O, Huag M, Strome M. Effects of adding steroids, in vitro irradiation, or both to cyclosporine immunosuppression in the murine laryngeal transplantation model.  Ann Otol Rhinol Laryngol. 2002;  111 455-459
• 15 U.S. Multicenter Liver Study Group . A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation.  N Engl J Med. 1994;  331 1110-1115
• 16 Suthanthiran M, Strom T. Immunobiology and immunopharmacology of organ allograft rejection.  J Clin Immunol. 1995;  15 161-171
• 17 Ahsan N, Johnson C, Gonwa T et al.. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.  Transplantation. 2001;  72 245-250
• 18 Eckoff D E, McGuire B, Frenette L et al.. Tacrolimus (FK506) and mycophenolate mofetil combination therapy vs tacrolimus in adult liver transplantation.  Transplantation. 1998;  65 180-187
• 19 Hunt S A. New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus.  Cardiol Rev. 2000;  8 180-184
• 20 Reichenspurner H, Kur F, Treede H et al.. Optimization of an immunosuppressive protocol after lung transplantation.  Transplantation. 1999;  68 67-71
• 21 Nelson M, Fritz M, Dan O et al.. Tacrolimus and mycophenolate mofetil provide effective immunosuppression in rat laryngeal transplantation.  Laryngoscope. 2003;  113 1308-1313
• 22 Akst L M, Siemionow M, Dan O et al.. Induction of tolerance in a rat model of laryngeal transplantation.  Transplantation. 2003;  76 1763-1770
• 23 Khariwala S S, Dan O, Lorenz R et al.. Pulsed immunosuppresion with everolimus and anti-αβ T-cell receptor: laryngeal allograft preservation at six months.  Ann Otol Rhinol Laryngol. 2006;  115 74-80
• 24 Schuler W, Sedrani R, Cottens S et al.. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.  Transplantation. 1997;  64 36-42
• 25 Kovarik J M, Kaplan B, Tedesco Silva H et al.. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.  Transplantation. 2002;  73 920-925
• 26 Neuhaus P, Klupp J, Langrehr J M. mTor inhibitors: an overview.  Liver Transpl. 2001;  7 473-484
• 27 Abraham R T, Wiederrecht G J. Immunopharmacology of rapamycin.  Annu Rev Immunol. 1996;  14 483-510
• 28 Schmidbauer G, Hancock W W, Wasowska B et al.. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production and cell adhesion.  Transplantation. 1994;  57 933-941
• 29 Huang S, Houghton P J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.  Curr Opin Investig Drugs. 2002;  3 295-304
• 30 Muthukkumar S, Ramesh T M, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells.  Transplantation. 1995;  60 264-270
• 31 Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70^s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells.  Cancer Res. 1996;  56 3895-3897
• 32 Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients.  Clin Transplant. 1998;  147-158
• 33 Khurana D, Martin E A, Kasperbauer J L et al.. Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy.  Head Neck. 2001;  23 899-906
• 34 Khariwala S S, Kjaergaard J, Lorenz R et al.. Everolimus (RAD) inhibits the growth of murine squamous cell carcinoma (SCC VII).  Laryngoscope. 2006;  116 814-820
• 35 Knott P D, Nelson M, Dan O, Van Lente F, Strome M. Immunosuppressive efficacy of everolimus and tacrolimus combination therapy in a rat laryngeal transplant model. (Submitted)
• 36 Lorenz R R, Hicks D M, Sheilds R W, Fritz M A, Strome M. Laryngeal nerve function after total laryngeal transplantation.  Otolaryngol Head Neck Surg. 2004;  131 1016-1018